Figitumumab (CP-751,871) for cancer therapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Targeted Therapy

Background:

• Figitumumab is a fully human IgG2 monoclonal antibody targeting the Insulin-like Growth Factor Type 1 Receptor (IGF-IR).
• IGF-IR signaling is implicated in various cancer types, making it a relevant therapeutic target.
• The development program for figitumumab began with early trials initiated in 2003.

Purpose of the Study:

• To review the rationale, preclinical data, and early clinical results of the figitumumab development program.
• To assess the potential of IGF-IR targeting in cancer treatment.
• To provide an overview of the figitumumab investigational program.

Main Methods:

• Review of preclinical studies evaluating figitumumab's efficacy and safety.
• Analysis of early-phase clinical trial data, including pharmacodynamics.
• Examination of tumor sensitivity mechanisms related to IGF-IR.

Main Results:

• Figitumumab demonstrated an effective half-life of approximately 20 days and was generally well-tolerated in clinical trials.
• Pharmacodynamic studies indicated that IGF-IR overexpression and IGF bioactivity are independent mechanisms of tumor sensitivity.
• Single-agent activity was observed in Ewing's sarcoma, with potential activity suggested in NSCLC.

Conclusions:

• The biological rationale for targeting IGF-IR in cancer is robust.
• Figitumumab can be feasibly combined with standard-of-care therapies.
• An expanded clinical program is justified due to unmet medical needs in oncology.